Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...
Browsing Tag: RATIONALE-309
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...